NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee approved inducement option grants covering 18,000 ordinary shares to one non-executive new hire under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee approved inducement option grants covering 18,000 ordinary shares to one non-executive new hire under the 2024 Inducement Plan and Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $37.00, equal to the Nasdaq closing price on the grant date of November 3, 2025. Vesting occurs over four years: 25% on the one-year anniversary of the vesting commencement date, then the remainder in 36 equal monthly installments, subject to continued service. Grants are subject to the 2024 Inducement Plan and the related option award agreement.
Details
News Market Reaction – NAMS
On Nov 10, the first trading day after this news, NAMS closed 6.01% above the previous close. That session’s volume was 1.7x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NAARDEN, The Netherlands and MIAMI, Nov. 07, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 18,000 of NewAmsterdam’s ordinary shares to one non-executive new hire. The share options were granted as an inducement material to the employee’s acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.